Shows
Talking Too Loud with Chris SavageGrowing Wistia Live with Senior Product Manager, Yooni Choi and Product Marketing Manager, Jean MerlainProduct launches are full of fanfare, but what happens after the big unveiling? How do you retain customers? How do you incorporate feedback? And how do you make sure you’re communicating the latest features the product offers? These are just some of the questions that Chris and Sylvie get into on the latest episode of Talking Too Loud. Alongside Wistia’s Senior Product Marketer, Yooni Choi, and Product Marketing Manager Jean Merlain, the quad peeks behind the product-curtain to explore the challenges and strategies involved in growing Wistia Live.Links to learn about Wistia Live:ht...
2024-05-2857 min
VIDEO MOJO with Jon Leland: Timeless marketing mixed with the bleeding edge of video & social mediaWhy Would Wistia Want to Add Webinars to Their Video Marketing Mix?In this episode of Video Mojo, B2B video marketing influencer Jon Leland of https://combridges.com interviews Jean Merlain, a Product Marketing Manager at Wistia, about the advantages of using the new Wistia Live platform to host webinars for B2B organizations. They discuss the differences between B2B and smaller creators’ video marketing approaches, the struggle of taking advantage of video's power, and the pandemic's impact on B2B marketing.
Jean Merlain shares insights on how B2B organizations can connect video marketing to their marketing automation platforms, track their performance, capture and nurture leads, an...
2023-03-1421 min
Talking Too Loud with Chris SavageLaunching Wistia Live with Jean Merlain and Delphine MahosWhat’s got Delphine talking too loud? The fact that her brain went totally blank when she was first asked that question, which led her to make a list of notable things, and she is now very glad to have said list. Also, sewing!Jean is talking too loud about basketball. He loves the game, he’s a Celtics fan, but the thing that’s getting his volume turned all the way up are the L.A. Lakers; they’re on the struggle bus, and it’s hard to watch. C’mon guys—do better!Links to learn...
2022-11-2245 min
Biotech2050 Podcast33.RNA modification gene therapy for rare disorders, Jim Burns, CEO, Kathie Bishop, CSO, LocanabioJames Burns, PhD, Chief Executive Officer, Locanabio
James (Jim) Burns, Ph.D., joined Locanabio in December 2019 as CEO and Board member. Prior to joining Locanabio, Dr. Burns served as the CEO of Casebia Therapeutics and led the team in discovering and developing new CRISPR/Cas9-based breakthrough therapeutics to treat blood disorders, blindness and auto-immune disease. Prior to Casebia, Dr. Burns spent the bulk of his career at Sanofi-Genzyme, where he held several leadership roles with increasing responsibility, including North America Site Head for R&D where he coordinated R&D operations across key...
2020-10-0727 min
Biotech2050 Podcast31. Drug discovery for neurodegenerative diseases, Victor Hanson-Smith, Comp. Bio., Verge GenomicsVictor Hanson-Smith is the Head of Computational Biology at Verge Genomics and is one of the world's leaders in mathematical modeling of eukaryotic genome evolution and function. He has co-authored 13 publications in peer-reviewed journals such as Nature and Science, and his work has been featured in the NYTimes and The Washington Post. He received his Ph.D. in Computer Science from the University of Oregon, and completed an NIH post-doctoral research fellowship in Evolutionary Genomics at UCSF. Additionally, he is a full-stack software engineer with 17 years experience building web applications, supercomputing simulations, and genomics pipelines.
2020-09-2421 min
Biotech2050 Podcast30. Genetics and synthetic biology for trailblazing drug discovery, Maria Soloveychik, CEO, SyntheXDr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation. SyntheX was founded in 2016 and is located in San Francisco.
Maria has obtained her PhD from the Department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics co...
2020-09-2417 min
Biotech2050 Podcast29. Breakthrough imaging device for noninvasive cancer detection: Bob Proulx, CEO Imagion BiosystemsBob has been President of Imagion Biosystems since February 2015 and has led the company through the recent restructuring and recapitalization efforts. Previous employment experience includes Pres/GM for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience in the computer, life science and medical diagnostics industries, e.g. Vice President Marketing and Sales for Nanogen, Inc., Senior Vice President of Marketing and Business Development at Gene Logic, and General Manager, Life Sciences at IGEN International, Inc. Mr. Proulx holds an M.A. and B.A. from The State University of New York at...
2020-09-0925 min
Biotech2050 Podcast28. Urology medtech for BPH with insights on patient care, VC, and more Nick Damiano, CEO, ZenflowNick Damiano is a serial entrepreneur with broad experience in medical devices and digital health. He has 15 years of experience as a healthcare entrepreneur, engineer, and leader. He is currently Co-Founder & CEO of Zenflow, which is developing a novel office-based therapy to relieve symptoms of benign prostatic hyperplasia (BPH), which affects over 500 million men globally. The company has raised over $40 million in funding and conducted successful clinical trials in four countries. Zenflow is backed by leading venture firms including Invus and F-Prime and was one of the first medical device companies funded by Y Combinator, the world’s leading st...
2020-09-0221 min
Biotech2050 Podcast27. Harnessing the microbiome to combat type 2 diabetes: Colleen Cutcliffe, CEO, PendulumColleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.
2020-08-2618 min
Biotech2050 Podcast26. DNA testing to proactively inform treatment. Paul Billings, CMO, NateraDr. Paul R. Billings is a board-certified internist and clinical geneticist, who also holds a PhD in Immunology, from Harvard University. He worked there with Dr. Baruj Benacerraf, who subsequently received the Nobel Prize in Medicine. In 2018, Dr. Billings became the Chief Medical Officer and Senior Vice President for Medical Affairs at Natera. Dr Billings recently has been a Partner in the diagnostic medicine consultancy the Bethesda Group, and the Managing Director of the Bethesda Group Fund. He is Chairman of PlumCare, LLc and Synergenz Biosciences Limited. He has held academic and research appointments at Harvard University, UC San...
2020-08-1935 min
Biotech2050 Podcast25. The power of AI for precision drug discovery and development: Auransa Inc., Andy Protter, CSOAndy Protter, PhD. joined Auransa in January 2017 as Chief Scientific Officer with 35 years of pharmaceutical industry research and development experience. At Auransa, Dr. Protter has led preclinical R&D which uses AI technology to discover novel drug candidates. Auransa’s lead project for hepatocellular carcinoma has completed all IND-supporting preclinical safety studies.
Prior to joining Auransa, Dr. Protter was a Vice President at Medivation where he was responsible for preclinical pharmacology and toxicology of Enzalutamide, a prostate cancer drug that was approved by the FDA.
Prior to Medivation, Dr. Protter worked at Scios, a biotechnology co...
2020-08-0520 min
Biotech2050 Podcast21. Glenn Rosen, MD, Senior VP, Pre-Clinical Translational Sciences, Coherus BioSciencesDr. Glenn Rosen has spent the bulk of his career engaged in basic and translational research in cancer and fibrosis. From 1993-2014, Dr. Rosen held a tenured faculty position in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University. He led a basic and translational research laboratory-his research focused on the study of dysregulated signaling in fibrosis and mechanisms of apoptosis resistance in solid tumors. He also led the clinical Interstitial Lung Disease Program at Stanford. Dr. Rosen joined Bristol-Myers Squibb (BMS) in September 2014 as a Medical Director in the Early Clinical and Translational Research...
2020-07-2933 min
Biotech2050 Podcast24. JoyL Silva, GM, and Nicole Strauss Pipeline Development and Innovation Lead, Pfizer CentreOneJoyL is the General Manager of Pfizer CentreOne, a global contract development and manufacturing organization (CDMO) and a leading supplier of specialty APIs embedded within Pfizer. In 2019, under her leadership, Pfizer CentreOne contributed $810M in revenue with a growth rate of 9% while advancing Pfizer’s purpose of delivering breakthroughs that change patients’ lives. In 2020 Pfizer CentreOne received the Life Science Leader and Outsourced Pharma CMO Leadership Award for the fourth consecutive year, recognizing the strong partnerships built with customers.
JoyL began her 20+ year career at Pfizer as a healthcare representative and progressed through a series of sales, oper...
2020-07-2920 min
Biotech2050 Podcast23. Abbas Kazimi, VP of Business Development, Nimbus TherapeuticsAbbas Kazimi is the Vice President, Head of Business Development at Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine. Abbas joined Nimbus in 2014 as Director of Business Development and has driven several of the company’s key transactions that have brought over $775M into Nimbus through financings and transactions, including the exclusive licensing agreement with Genentech, the sale of Nimbus’ clinical NASH program to Gilead in and the multiple strategic alliances with Celgene.
Prior to joining Nimbus, Abbas spent a decade in planning, advising, and executing strat...
2020-07-2831 min
Biotech2050 Podcast22. Randy Schatzman, Ph.D.,CEO and Board Member, Bolt BiotherapeuticsDr. Randy Schatzman, Ph.D., is the chief executive officer and a board member of Bolt Biotherapeutics since 2019. He has over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior...
2020-07-1620 min
Biotech2050 Podcast20. Diego Ardigò, MD, PhD, Head of Research and Development, Global Rare Diseases, Chiesi GroupDiego is currently the Head of Research & Development of Global Rare Diseases at the Chiesi Group. Before this role, he was leading Chiesi’s development projects in rare diseases and advanced therapies and has more than 10 years experience in drug development, spanning from pre-clinical to commercial phase.
Diego is an MD with a specialization in Internal Medicine. He obtained a PhD at the University of Parma (Italy) in cardiovascular pathophysiology and a post-doctoral fellowship in cardiovascular genomics at Stanford University (California, US).
Before joining the industry, he worked at the University of Parma (Italy) in th...
2020-07-0122 min
Biotech2050 Podcast19. Mike Clayman, M.D, CEO and Co-Founder, Flexion TherapeuticsDr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer and as one of our directors since our inception in 2007. Dr. Clayman also serves as the Chairman of the board of directors of both Anokion SA and Ribometrix. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division, the Cardiovascular Discovery Research and Clinical Investigation, Research an...
2020-06-2425 min
Biotech2050 Podcast18. Grace Colón, PhD, President and CEO, InCarda TherapeuticsDr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she is Executive Chairman (formerly CEO) of ProterixBio, and serves on the boards of CareDx (NASDAQ:CDNA) and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. Formerly, she was a partner at New Science Ventures, a New York based venture capital firm with over $700M under management, and served on the boards of Paradigm Diagnostics and PerceptiMed.
Previously, she co-founded Pyranose Biotherapeutics, a...
2020-06-1722 min
Biotech2050 Podcast17. Sachin Chandran, PhD, Exec. Dir., Head of Pharmaceutical Sciences, Catabasis PharmaceuticalsRecorded in January 2020, we spoke with Sachin Chandran, who is currently Executive Director and Head of Pharmaceutical Sciences at Catabasis Pharmaceuticals, Inc. in Boston. Sachin’s responsibilities include oversight of CMC, Tech-Ops and supply chain along with matrixed interactions with regulatory, quality, biology, clinical and commercial. Working in a lean organization and a virtual environment, Sachin brings a strategic mindset while operationalizing with a can-do attitude with the goal to aid in the successful development and commercialization of edasalonexent.
Previously, Sachin has been at Vertex Pharmaceuticals, Inc. and Bristol Myers Squibb Co. in roles of increasing responsibility, co...
2020-06-1023 min
Biotech2050 Podcast16. Mike Novotny, Founder and CEO, MedrioMike Novotny is the founder and CEO of Medrio. Mr. Novotny applies 20 years of experience in research and software to his eClinical SaaS vision. Prior to founding Medrio, Mr. Novotny was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA. He holds a BA from Stanford University and an MBA from Columbia University. Mr. Novotny founded Medrio in 2005 in San Francisco.
2020-06-0334 min
Biotech2050 Podcast15. David Mace, Co-Founder and CEO, SwiftScale BiologicsDavid Mace is the Co-founder & CEO of SwiftScale Biologics, a life sciences startup based in San Francisco, California. SwiftScale Biologics accelerates time to market for protein drugs by turning a labor-intensive drug production scale-up challenge into a computational challenge. Previously David was an Entrepreneur in Residence at 8VC, where he focused on the intersection of biology & computer science. He is a graduate of the California Institute of Technology.
2020-05-2729 min
Biotech2050 Podcast14. David Bates, PhD, Co-Founder, Linus HealthDavid Bates is a scientist, inventor, investor, and entrepreneur. He has co-founded several companies including Linus Health and Bode. He is a founding partner of Tamarisc Ventures and serves on the board of several high-growth technology companies. He is on the board of directors of TMCity Foundation and is Strategic Advisor to the Digital Medicine Society. He previously worked at Morningside Ventures where he focused on biotech, healthcare, and cleantech investments.
David was also the Chief Strategy Officer for F-Wave, a building technology company and Morningside portfolio company He helped with the acquisition of Fuji Solar in Ja...
2020-05-1934 min
Biotech2050 Podcast13. Stephan Kontos, PhD, Co-Founder and CSO, AnokionStephan is a co-Founder and Chief Scientific Officer at Anokion, bringing more than 15 years of research expertise in the fields of immunology, protein engineering, and platform technologies to the company. He earned his B.Sc. in Chemical Engineering from the University of Texas at Austin and a Ph.D. in Bioengineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne. During his thesis work, Stephan co-invented and developed the immune tolerance technology platform that inspired the founding of Anokion and its spin-off company Kanyos Bio. As a founding member of the executive leadership team, he has played a...
2020-05-1331 min
Biotech2050 Podcast12. Robert Gould, PhD, President & CEO, and Owen Wallace, PhD, CSO, Fulcrum TherapeuticsRobert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. During his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in...
2020-05-0433 min
Biotech2050 Podcast11. Paul Wotton, PhD, CEO, Obsidian TherapeuticsDr. Paul K. Wotton is Obsidian’s Chief Executive Officer, bringing significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton most recently served as the Founding President and CEO of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, he served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is...
2020-04-2729 min
Biotech2050 Podcast10. Chris Murray, Sr. VP, Technical Operations, Blueprint MedicinesChris is Sr. Vice President, Technical Operations at Blueprint Medicines. He has over 25 years of commercial and clinical manufacturing experience in the biopharmaceutical industry and has been fortunate to help develop and commercialize numerous oncology medicines. He has been in his current role since October 2017.
2020-02-2632 min
Biotech2050 Podcast9. Carl P. Decicco, PhD, CSO, Foghorn TherapeuticsCarl P. Decicco is a biopharmaceutical veteran with over 30+ years of experience in the industry. Over the course of his career, Carl has played a central role in the advancement of more than 200 compounds into clinical trials and the approval of more than 20 drugs across multiple therapeutic areas. He’s authored/Co-Authored more than 100 scientific papers in peer reviewed journals and is listed as an inventor on 26 patents.
2020-01-2327 min
Biotech2050 Podcast8. Dr. Florian Wegener, Co-Founder and CEO of ZAGENODr. Florian Wegener is the co-founder and CEO of ZAGENO, an award-winning online marketplace serving the needs of research scientists. He is also a board-certified physician.
2020-01-0734 min
Biotech2050 Podcast7. Raman Sehgal, Founder and Global President of RamarketingRaman is the founder and global president of ramarketing - an international design, digital and PR agency that's in the business of helping ambitious contract service companies operating in the global biotech and pharmaceutical outsourcing sector get noticed.
2019-12-1726 min
Biotech2050 Podcast6. Kevin J. Bittorf, PhD: Consultant and Founder, Simulation LLCIn this episode, guest Kevin Bittorf, founder of the Advancing Drug Development Forum and Dawn Dickerson sat down with host Alok Tayi to discuss trends in modern manufacturing and pharmaceutical environments.
Kevin Bittorf is an accomplished Senior Executive and Consultant with demonstrated success and a proven track record in pharmaceutical development, technical Innovation, and IoT.
2019-12-1022 min
Biotech2050 Podcast5. Jon Hennek: Systems Innovation Team Co-Lead at Indigo AgJon Hennek co-leads the Systems Innovation Team at Indigo Ag. He co-founded the team—whose mission is to create a vision for what agriculture could look like in the distant future and develop a strategy for the Indigo model to dramatically accelerate its adoption—in 2017 while at Flagship Pioneering.
2019-12-0330 min
Biotech2050 Podcast4. Sven Karlsson: Co-founder, COO and CBO of Platelet BioGenesisSven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. He has more than a decade of experience in business development and financial analysis.
2019-11-0526 min
Biotech2050 Podcast3. Dr. Jo Viney: Co-Founder, President and CSO of Pandion TherapeuticsDr. Jo Viney is an entrepreneurial scientist and experienced biotech executive. A self-described “drug-hunter”, she has successfully advanced a number of programs into the clinic.
She is Co-Founder, President and CSO of Pandion Therapeutics, a startup company in Cambridge, MA focused on developing new therapies for treating autoimmune and inflammatory diseases.
2019-10-2926 min
Biotech2050 Podcast2. John Keilty: Chief Data Sciences Officer at Decibel TherapeuticsJohn Keilty is the Chief Data Sciences Officer at Decibel Therapeutics and a Strategic advisor at Third Rock Ventures. He is a biologist and bioinformatics guy by training and has been active in the biotech space for over two decades. In his career, John has been responsible for building out genomix, and genetics capabilities for early stage biotech companies.
In this episode of Biotech 2050, John goes through his journey into the biotech industry and the work he’s doing at Decibel Therapeutics and Third Rock Ventures.
2019-10-2327 min
Biotech2050 Podcast1. Lee Cooper: Patient advocate and Founder of Enlight BioIn this inaugural episode of Biotech2050, hosts Alok Tayi and Rahul Chaturvedi sits down with Lee Cooper, a seasoned biotech entrepreneur, patient advocate, and Founder of Enlight Bio to talk about the importance of patient centricity in today’s modern biotech.
Cooper talked about his journey to the Biotech industry and how he came to founding Enlight Bio.
2019-10-1538 min
Biotech2050 PodcastWelcome to the Biotech2050 PodcastThis episode is a trailer launching our highly anticipated podcast, Biotech 2050. A Think Tank chronicling the disruptions changing the biotech industry over the next 50 years.
2019-10-0201 min